72 related articles for article (PubMed ID: 35562406)
1. Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial.
Ferreri AJM; Cwynarski K; Pulczynski E; Fox CP; Schorb E; Celico C; Falautano M; Nonis A; La Rosée P; Binder M; Fabbri A; Ilariucci F; Krampera M; Roth A; Hemmaway C; Johnson PW; Linton KM; Pukrop T; Gørløv JS; Balzarotti M; Hess G; Keller U; Stilgenbauer S; Panse J; Tucci A; Orsucci L; Pisani F; Zanni M; Krause SW; Schmoll HJ; Hertenstein B; Rummel M; Smith J; Thurner L; Cabras G; Pennese E; Ponzoni M; Deckert M; Politi LS; Finke J; Ferranti A; Cozens K; Burger E; Ielmini N; Cavalli F; Zucca E; Illerhaus G;
Leukemia; 2022 Jul; 36(7):1870-1878. PubMed ID: 35562406
[TBL] [Abstract][Full Text] [Related]
2. Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients.
Schorb E; Finke J; Ihorst G; Kasenda B; Fricker H; Illerhaus G
BMC Cancer; 2019 Mar; 19(1):287. PubMed ID: 30925912
[TBL] [Abstract][Full Text] [Related]
3. Survival, neurocognitive function, and health-related quality of life outcomes after rituximab-methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma: Final results of the HOVON 105/ALLG NHL 24 study.
Bromberg JEC; Issa S; van der Holt B; van der Meulen M; Dirven L; Minnema MC; Seute T; Durian M; Cull G; van der Poel MWM; Stevens WBC; Zijlstra JM; Brandsma D; Nijland M; Mason KD; Beeker A; Abrahamse-Testroote MCJ; van den Bent MJ; de Jong D; Doorduijn JK
Neuro Oncol; 2024 Apr; 26(4):724-734. PubMed ID: 38037691
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment of isolated central nervous system recurrence of primary testicular lymphoma by autologous stem cell transplantation using a conditioning regimen of thiotepa and busulfan.
Tanaka Y; Sakai T; Tsunemine H; Ito T; Arima N
J Clin Exp Hematop; 2024 Mar; 64(1):32-36. PubMed ID: 38417873
[TBL] [Abstract][Full Text] [Related]
5. Impact of thiotepa dose-intensity in primary diffuse large B-cell lymphoma of the central nervous system undergoing autologous hematopoietic cell transplant with thiotepa/carmustine conditioning.
Arshad S; Fang X; Ahn KW; Kaur M; Scordo M; Sauter CS; Furqan F; Awan FT; Hamadani M
Bone Marrow Transplant; 2023 Nov; 58(11):1203-1208. PubMed ID: 37563283
[TBL] [Abstract][Full Text] [Related]
6. Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers.
David KA; Sundaram S; Kim SH; Vaca R; Lin Y; Singer S; Malecek MK; Carter J; Zayac A; Kim MS; Reddy N; Ney D; Habib A; Strouse C; Graber J; Bachanova V; Salman S; Vendiola JA; Hossain N; Tsang M; Major A; Bond DA; Agrawal P; Mier-Hicks A; Torka P; Rajakumar P; Venugopal P; Berg S; Glantz M; Goldlust SA; Folstad M; Kumar P; Ollila TA; Cai J; Spurgeon S; Sieg A; Cleveland J; Chang J; Epperla N; Karmali R; Naik S; Martin P; Smith SM; Rubenstein J; Kahl B; Evens AM
Am J Hematol; 2023 Jun; 98(6):900-912. PubMed ID: 36965007
[TBL] [Abstract][Full Text] [Related]
7. Myeloablative Vs. Non-Myeloablative Consolidation for Primary Central Nervous System Lymphoma: Results of Alliance 51101.
Batchelor TT; Giri S; Ruppert AS; Geyer S; Smith SE; Mohile N; Swinnen LJ; Friedberg JW; Kahl BS; Bartlett NL; Hsi ED; Cheson BD; Wagner-Johnston ND; Nayak L; Leonard JP; Rubenstein JL
Blood Adv; 2024 Apr; ():. PubMed ID: 38598710
[TBL] [Abstract][Full Text] [Related]
8. Management of central nervous system relapse in a young patient affected by primary mediastinal large B-cell lymphoma: A case report.
Marangon M; Casadei B; Broccoli A; Argnani L; Cavo M; Zinzani PL
Clin Case Rep; 2020 Jun; 8(6):933-937. PubMed ID: 32577237
[TBL] [Abstract][Full Text] [Related]
9. Primary central nervous system lymphoma.
Ferreri AJM; Calimeri T; Cwynarski K; Dietrich J; Grommes C; Hoang-Xuan K; Hu LS; Illerhaus G; Nayak L; Ponzoni M; Batchelor TT
Nat Rev Dis Primers; 2023 Jun; 9(1):29. PubMed ID: 37322012
[TBL] [Abstract][Full Text] [Related]
10. Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients Age 60 Years and Younger: Long-Term Results of the Randomized Phase II PRECIS Study.
Houillier C; Dureau S; Taillandier L; Houot R; Chinot O; Moluçon-Chabrot C; Schmitt A; Gressin R; Choquet S; Damaj G; Peyrade F; Abraham J; Delwail V; Gyan E; Sanhes L; Cornillon J; Garidi R; Delmer A; Al Jijakli A; Morel P; Waultier A; Paillassa J; Chauchet A; Gastinne T; Laadhari M; Plissonnier AS; Feuvret L; Cassoux N; Touitou V; Ricard D; Hoang-Xuan K; Soussain C;
J Clin Oncol; 2022 Nov; 40(32):3692-3698. PubMed ID: 35834762
[No Abstract] [Full Text] [Related]
11. Primary CNS lymphoma: update on molecular pathogenesis and therapy.
Mo SS; Cleveland J; Rubenstein JL
Leuk Lymphoma; 2023 Jan; 64(1):57-65. PubMed ID: 36286546
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase III study of high-dose methotrexate and whole-brain radiotherapy with/without temozolomide for newly diagnosed primary CNS lymphoma: JCOG1114C.
Mishima K; Nishikawa R; Narita Y; Mizusawa J; Sumi M; Koga T; Sasaki N; Kinoshita M; Nagane M; Arakawa Y; Yoshimoto K; Shibahara I; Shinojima N; Asano K; Tsurubuchi T; Sasaki H; Asai A; Sasayama T; Momii Y; Sasaki A; Nakamura S; Kojima M; Tamaru JI; Tsuchiya K; Gomyo M; Abe K; Natsumeda M; Yamasaki F; Katayama H; Fukuda H
Neuro Oncol; 2023 Apr; 25(4):687-698. PubMed ID: 36334050
[TBL] [Abstract][Full Text] [Related]
13. Treatment Options for Recurrent Primary CNS Lymphoma.
Kaulen LD; Baehring JM
Curr Treat Options Oncol; 2022 Nov; 23(11):1548-1565. PubMed ID: 36205806
[TBL] [Abstract][Full Text] [Related]
14. Optimizing MATRix as remission induction in PCNSL: de-escalated induction treatment in newly diagnosed primary CNS lymphoma.
Wendler J; Fox CP; Valk E; Steinheber C; Fricker H; Isbell LK; Neumaier S; Okosun J; Scherer F; Ihorst G; Cwynarski K; Schorb E; Illerhaus G
BMC Cancer; 2022 Sep; 22(1):971. PubMed ID: 36088292
[TBL] [Abstract][Full Text] [Related]
15. Long-term Outcomes in Primary CNS Lymphoma After R-MVP and High-Dose Chemotherapy With Autologous Hematopoietic Stem Cell Transplant.
Therkelsen KE; Schaff LR; Nandakumar S; Omuro AMP; DeAngelis LM; Grommes C
Neurology; 2023 Aug; 101(7):e710-e716. PubMed ID: 37344228
[TBL] [Abstract][Full Text] [Related]
16. Radiotherapy or chemotherapy: a real-world study of the first-time relapsed and refractory primary central nervous system lymphoma.
Yang Y; Li Q; Ma J; Kang H; Lin Z; Wang Y; Ma Y; Chen B
Front Oncol; 2023; 13():1098785. PubMed ID: 37182159
[TBL] [Abstract][Full Text] [Related]
17. Thiotepa, Busulfan, Cyclophosphamide: Effective but Toxic Conditioning Regimen Prior to Autologous Hematopoietic Stem Cell Transplantation in Central Nervous System Lymphoma.
Delphine L; Pierre-Edouard D; Bruno R; Bérengère G; Magalie J; Patrick V; Jean-Pierre M; Pierre M
Med Sci (Basel); 2023 Jan; 11(1):. PubMed ID: 36810481
[TBL] [Abstract][Full Text] [Related]
18. CSF biomarkers in primary CNS lymphoma.
Nguyen-Them L; Alentorn A; Ahle G; Soussain C; Mathon B; Le Garff Tavernier M; Houillier C; Hoang-Xuan K
Rev Neurol (Paris); 2023 Mar; 179(3):141-149. PubMed ID: 36336490
[TBL] [Abstract][Full Text] [Related]
19. Case report: Successful treatment of a patient with relapsed/refractory primary central nervous system lymphoma with thiotepa-based induction, autologous stem cell transplantation and maintenance.
Wang L; Fan Y; Chen B; Zhang J; Yang L; Qiu X; Jiang H; Li J; Xiao X; Huang L; Xu Y
Front Oncol; 2023; 13():1333761. PubMed ID: 38348121
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
